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EDITORIALKruppel-like Factor 14 as Driver of Regulatory T-Cell Activity
in Intestinal Inﬂammationegulatory T cells (Treg cells) have been previouslyRfound to play a major role in controlling chronic
intestinal inﬂammation. In the murine model of colitis
induced by adoptive transfer of CD4þCD45RBhigh T cells,
Treg cells produce anti-inﬂammatory cytokines such as
interleukin-10 and transforming growth factor-b and can
suppress intestinal inﬂammation by inhibiting effector
T-cell activity and expansion.1,2 Such effects can be obtained
by cotransfer of either naturally occurring Treg cells or
inducible Treg cells that have been expanded in vitro.1,3 It
may therefore be surprising that the expansion of func-
tionally active mucosal Treg cells found in patients with
inﬂammatory bowel diseases (IBD) fails to prevent or
reverse disease. This is likely explained by the massive
expansion of effector T cells in IBD, which leads to a
reduction in the ratio between Treg cells and effector T cells,
even though the number of both cell types is increased.4
This concept has led to initial trials to suppress chronic
intestinal inﬂammation in IBD patients by adoptive transfer
of expanded naturally occurring Treg cells.5 Collectively,
these ﬁndings highlight the crucial relevance of Treg cells in
intestinal inﬂammation. However, the molecular signals that
drive functional activity of Treg cells in the inﬂamed mucosa
in colitis are poorly understood.
In the present issue of Cellular and Molecular Gastroen-
terology and Hepatology, Sarmento et al6 have analyzed
potential regulators of Treg activity in chronic intestinal
inﬂammation. They identiﬁed Kruppel-like factor 14
(KLF14) as an important regulator of Treg function. Spe-
ciﬁcally, KLF14 was found to control the expression of
forkhead box P3 (FoxP3), the master transcription factor of
Treg cells, via transcriptional mechanisms involving
methylation and chromatin remodeling at the Treg-speciﬁc
demethylation region (TSDR) within the promoter. Inacti-
vation of KLF14 led to hyperactivation of Treg cells and
augmented their suppressive capacities.
To analyze the relevance of KLF14 in intestinal inﬂam-
mation in vivo, they performed additional studies using both
dextran sodium sulfate and CD4þCD45RBhigh adoptive
transfer colitis models. In the dextran sodium sulfate colitis
model, KLF14 deﬁciency reduced the severity of the colitis,
consistent with the idea that augmented Treg activity pro-
tects mice from colitis. Similarly, transfer of KLF14-deﬁcient
or wild-type CD4þCD25þ T reg cells 14 days after adoptive
transfer of wild-type CD4þCD45RBhigh T cells showed that
KLF14-deﬁcient Treg cells were far superior in preventing
disease progression.
This study has therefore identiﬁed KLF14 as new nega-
tive regulator of the functional activity of FoxP3-expressing
mucosal Treg cells in colitis by directly inhibiting FoxP3
expression. Consistent with this idea, the investigatorsCellunoted that KLF14 and FoxP3 expression levels in mucosal
CD4þ T cells are inversely correlated in Crohn’s disease,
where KLF14 expression is reduced while FoxP3 expression
is increased as compared with control subjects.
These new ﬁndings provide insight into the mechanisms
controlling Treg activity and suggest novel approaches to
modulation of KLF14 expression as a therapeutic approach.
For example, suppression of KLF14 expression may repre-
sent an effective means of increasing Treg cells activity in
IBD patients.5 This would require further work, as tech-
nologies to efﬁciently silence KLF14 expression in vivo in
human Treg cells are not yet available. Furthermore, the
ﬁndings in this study may have broader relevance for other
autoimmune and chronic inﬂammatory disorders in which
insufﬁcient Treg cell activity has been reported. Future
studies should address KLF14 levels in such disorders to
clarify whether modulation of KLF14 is speciﬁcally relevant
for intestinal Treg cells or Treg cells in general in a variety
of chronic inﬂammatory diseases.
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